{"title":"治疗一例近期新冠肺炎感染的难治性抗黑色素瘤分化相关基因5抗体相关皮肌炎","authors":"Cheryl Chun Man Ng, A. Leung","doi":"10.1142/s266134172372001x","DOIUrl":null,"url":null,"abstract":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis is known to associate with rapidly progressive interstitial lung disease and cutaneous ulcer. The prognosis is often poor even with intensive treatment, with data from the local cohort showing 37.9% mortality [1]. Here, we report a case of refractory anti-MDA5 antibody-associated dermatomyositis that occurs shortly after COVID-19 infection and was managed using a combination of treatments that target different aspects of disease pathology.","PeriodicalId":15538,"journal":{"name":"Journal of Clinical Rheumatology and Immunology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Managing a Case of Refractory Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Dermatomyositis with Recent COVID-19 Infection\",\"authors\":\"Cheryl Chun Man Ng, A. Leung\",\"doi\":\"10.1142/s266134172372001x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis is known to associate with rapidly progressive interstitial lung disease and cutaneous ulcer. The prognosis is often poor even with intensive treatment, with data from the local cohort showing 37.9% mortality [1]. Here, we report a case of refractory anti-MDA5 antibody-associated dermatomyositis that occurs shortly after COVID-19 infection and was managed using a combination of treatments that target different aspects of disease pathology.\",\"PeriodicalId\":15538,\"journal\":{\"name\":\"Journal of Clinical Rheumatology and Immunology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Rheumatology and Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1142/s266134172372001x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Rheumatology and Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1142/s266134172372001x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Managing a Case of Refractory Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Dermatomyositis with Recent COVID-19 Infection
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis is known to associate with rapidly progressive interstitial lung disease and cutaneous ulcer. The prognosis is often poor even with intensive treatment, with data from the local cohort showing 37.9% mortality [1]. Here, we report a case of refractory anti-MDA5 antibody-associated dermatomyositis that occurs shortly after COVID-19 infection and was managed using a combination of treatments that target different aspects of disease pathology.